These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31548527)

  • 1. Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality.
    Tam SH; McCarthy SG; Armstrong AA; Somani S; Wu SJ; Liu X; Gervais A; Ernst R; Saro D; Decker R; Luo J; Gilliland GL; Chiu ML; Scallon BJ
    Antibodies (Basel); 2017 Sep; 6(3):. PubMed ID: 31548527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.
    Jacobsen FW; Stevenson R; Li C; Salimi-Moosavi H; Liu L; Wen J; Luo Q; Daris K; Buck L; Miller S; Ho SY; Wang W; Chen Q; Walker K; Wypych J; Narhi L; Gunasekaran K
    J Biol Chem; 2017 Feb; 292(5):1865-1875. PubMed ID: 27994062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors.
    Derebe MG; Nanjunda RK; Gilliland GL; Lacy ER; Chiu ML
    Immunol Lett; 2018 May; 197():1-8. PubMed ID: 29476755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
    Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
    Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of deglycosylated human IgG4-Fc.
    Davies AM; Jefferis R; Sutton BJ
    Mol Immunol; 2014 Nov; 62(1):46-53. PubMed ID: 24956411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
    Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
    MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.
    Liu L; Jacobsen FW; Everds N; Zhuang Y; Yu YB; Li N; Clark D; Nguyen MP; Fort M; Narayanan P; Kim K; Stevenson R; Narhi L; Gunasekaran K; Bussiere JL
    J Biol Chem; 2017 Feb; 292(5):1876-1883. PubMed ID: 27994063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.
    Zhang W; Chen X; Chen X; Li J; Wang H; Yan X; Zha H; Ma X; Zhao C; Su M; Hong L; Li P; Ling Y; Zhao W; Xia Y; Li B; Zheng T; Gu J
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering IgG1 Fc Domains That Activate the Complement System.
    Lee CH; Delidakis G
    Methods Mol Biol; 2022; 2421():187-200. PubMed ID: 34870820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered Fc-glycosylation switch to eliminate antibody effector function.
    Zhou Q; Jaworski J; Zhou Y; Valente D; Cotton J; Honey D; Boudanova E; Beninga J; Rao E; Wei R; Mauriac C; Pan C; Park A; Qiu H
    MAbs; 2020; 12(1):1814583. PubMed ID: 32892677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.
    Borghi S; Bournazos S; Thulin NK; Li C; Gajewski A; Sherwood RW; Zhang S; Harris E; Jagannathan P; Wang LX; Ravetch JV; Wang TT
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12943-12951. PubMed ID: 32461366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
    Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
    Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG subclasses and allotypes: from structure to effector functions.
    Vidarsson G; Dekkers G; Rispens T
    Front Immunol; 2014; 5():520. PubMed ID: 25368619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
    Huang Z; Pang X; Zhong T; Qu T; Chen N; Ma S; He X; Xia D; Wang M; Xia M; Li B
    Front Immunol; 2022; 13():924542. PubMed ID: 35833116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.